How did STE's revenue and expenses perform in Q1 2025 compared to previous quarters?


Aime
Steris (STE) experienced a notable increase in revenue and a slight improvement in expenses in Q1 2025 compared to the previous quarter, Q4 2024.
- Revenue Performance:
- In Q1 2025, Steris reported a total revenue of $1.37 billion from continuing operations, which represents a 5.6% year-over-year increase12.
- This growth was primarily driven by strong performances in the Healthcare and Applied Sterilization Technologies (AST) segments. Healthcare segment revenues rose by 7% to $976.0 million, while AST revenues improved by 10% to $258.1 million2.
- Organic revenues at constant exchange rate (CER) showed a robust increase of 6% year-over-year1.
- Expense Performance:
- The adjusted operating margin for Q1 2025 expanded by 61 basis points to 18.1%, indicating improved profitability1.
- The company's cash and cash equivalents decreased from $172.2 million at the end of Q2 2024 to $155.2 million in Q1 20251.
- Comparative Analysis:
- Q1 2025's revenue growth of 5.6% was slightly lower than the 6% increase reported in Q3 20242.
- The adjusted EPS of $2.32 in Q1 2025 was in line with expectations and represented a 9.9% increase from the previous year13.
- Net income for Q1 2025 was $173.6 million, up from $148.4 million in Q4 2024, indicating a strong financial performance2.
STE Total Revenue
In conclusion, Steris demonstrated solid revenue growth and improved profitability in Q1 2025, driven by strong segmental performances, particularly in Healthcare and AST, which contributed to the company's overall financial strength.
Source:
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
Wiki